+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell and Gene Therapy Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 140 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780634
The global cell and gene therapy market size is projected to experience significant growth during the forecast period of 2023-2031, driven by the increasing prevalence of chronic diseases, advancements in gene editing technologies, and the rising demand for personalized medicine. The market is expected to grow at a CAGR of 23% during the forecast period to attain a value of USD 113.648 billion by 2031.

Cell and Gene Therapy Market: Introduction

The global cell and gene therapy (CGT) market report provides an in-depth analysis of the market and its segments. Cell and gene therapies are advanced therapies that involve the use of living cells and genetic material to treat diseases. The report covers the market for CGT and provides a detailed analysis of the market size, growth, and trends.

The CGT market is expected to experience significant growth in the coming years due to the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases, and the rising demand for innovative treatment options. Additionally, the increasing focus on personalized medicine and the adoption of advanced healthcare infrastructure are likely to create lucrative opportunities for the market players.

Furthermore, the increasing investments in research and development activities, coupled with the growing number of clinical trials, are expected to fuel the growth of the market. The adoption of favourable government policies and the increasing demand for better healthcare services in emerging economies are expected to further contribute to the growth of the market.

Cell and Gene Therapy Market - Application and Usage

Cell and gene therapy are advanced therapeutic techniques that use living cells or genetic material to treat a variety of diseases. They hold great promise in the treatment of various medical conditions, including genetic disorders, cancer, cardiovascular diseases, and autoimmune diseases.

Here are some of the applications and uses of cell and gene therapy:

  • Cancer Treatment: Cell and gene therapy offer a new approach to treating cancer by using modified immune cells to target and destroy cancer cells. This therapy has shown promising results in treating various types of cancer, such as leukaemia and lymphoma
  • Genetic Disorders: Cell and gene therapy can correct genetic mutations that cause inherited disorders, such as sickle cell anaemia, haemophilia, and cystic fibrosis. This therapy involves inserting a normal copy of the gene into the patient's cells to restore their function
  • Cardiovascular Diseases: Cell and gene therapy are being explored as a potential treatment for cardiovascular diseases such as heart failure and myocardial infarction. This therapy involves the use of stem cells to regenerate damaged heart tissue and improve heart function
  • Autoimmune Diseases: Cell and gene therapy can modify immune cells to reduce the body's autoimmune response and treat autoimmune diseases such as multiple sclerosis and rheumatoid arthritis
  • Ophthalmology: Cell and gene therapy are being explored as a treatment for inherited and acquired eye diseases, such as retinitis pigmentosa and age-related macular degeneration. This therapy involves the use of gene therapy to restore vision by repairing or replacing damaged cells in the retina
  • Orthopaedics: Cell and gene therapy are being explored as a potential treatment for orthopaedic conditions such as osteoarthritis and bone fractures. This therapy involves the use of stem cells to regenerate damaged bone and cartilage tissue and promote healing

Cell And Gene Therapy Market Segmentations

The market can be categorised into type, indication, product type, end user, and major region.

Market Breakup by Type

Cell Therapy Types

  • Autologous Cell Therapy
  • Autogenic Cell Therapy
  • Ex-vivo Cell Therapy
  • In-vivo Cell Therapy

Gene Therapy Types

  • Somatic Cell Gene Therapy
  • Germline Gene Therapy
  • Ex-vivo Gene Therapy
  • In-vivo Gene Therapy

Market Breakup by Indications

  • Oncology
  • Cardiology
  • CNS
  • Musculoskeletal
  • Infectious Diseases
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Immunology and Inflammation
  • Ophthalmology
  • Haematology
  • Gastroenterology
  • Others

Market Breakup by Product Type

  • Yescarta
  • Provenge
  • Luxtura
  • Kymriah
  • Imlygic
  • Gintuit
  • MACI
  • Laviv
  • Gendicine
  • Oncorine
  • Neovasculgen
  • Strimvelis
  • Invossa
  • Zolgenesma
  • Tecartus
  • Lisocel
  • Zyntelego
  • Others

Cell and Gene Therapy Market Breakup by End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Wound Care Centres
  • Cancer Care Centres
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cell and Gene Therapy Market Scenario

The market is expected to experience significant growth in the coming years. The market is driven by the increasing prevalence of chronic diseases, advancements in gene editing technologies, and the rising demand for personalized medicine.

North America dominates the cell and gene therapy market, followed by Europe and the Asia Pacific. The high prevalence of chronic diseases, coupled with favourable government policies and the availability of advanced healthcare infrastructure, is driving the growth of the market in North America and Europe. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing prevalence of chronic diseases and rising healthcare expenditure in the region.

The oncology segment dominates the cell and gene therapy market by therapeutic application, followed by cardiovascular diseases and central nervous system disorders. The increasing prevalence of cancer and the rising demand for innovative cancer treatments are driving the growth of the oncology segment. The cell therapy segment dominates the market by therapeutic modality, followed by gene therapy and tissue engineering. The increasing demand for personalized medicine and the growing number of clinical trials are driving the growth of the cell therapy segment.

Key Players in the Global Cell and Gene Therapy Market

The report gives an in-depth analysis of the key players involved in the cell and gene therapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Amgen, Inc
  • Bluebird Bio, Inc
  • Castle Creek Pharmaceutical Holdings
  • Kite Pharma, Inc
  • Novartis AG
  • Orchard Therapeutics plc
  • Pfizer, Inc
  • Spark Therapeutics, Inc
  • Vericel Corporation
  • Human Stem Cells Institute
  • Kolon Tissuegene Inc
  • Organogenesis Holdings Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell and Gene Therapy Market Overview
3.1 Global Cell and Gene Therapy Market Historical Value (2016-2022)
3.2 Global Cell and Gene Therapy Market Forecast Value (2023-2031)
4 Global Cell and Gene Therapy Market Landscape
4.1 Global Cell and Gene Therapy Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cell and Gene Therapy Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
4.2.3 Analysis by End Users
5 Global Cell and Gene Therapy Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cell and Gene Therapy Market Segmentation
6.1 Global Cell and Gene Therapy Market by Type
6.1.1 Market Overview
6.1.2 Cell Therapy Types
6.1.2.1 Autologous Cell Therapy
6.1.2.2 Autogenic Cell Therapy
6.1.2.3 Ex-vivo Cell Therapy
6.1.2.4 In-vivo Cell Therapy
6.1.3 Gene Therapy Types
6.1.3.1 Somatic Cell Gene Therapy
6.1.3.2 Germline Gene Therapy
6.1.3.3 Ex-vivo Gene Therapy
6.1.3.4 In-vivo Gene Therapy
6.2 Global Cell and Gene Therapy Market by Indications
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiology
6.2.4 CNS
6.2.5 Musculoskeletal
6.2.6 Infectious Diseases
6.2.7 Dermatology
6.2.8 Endocrine, Metabolic, Genetic
6.2.9 Immunology and Inflammation
6.2.10 Ophthalmology
6.2.11 Haematology
6.2.12 Gastroenterology
6.2.13 Others
6.3 Global Cell and Gene Therapy Market by Product Type
6.3.1 Market Overview
6.3.2 Yescarta
6.3.3 Provenge
6.3.4 Luxtura
6.3.5 Kymriah
6.3.6 Imlygic
6.3.7 Gintuit
6.3.8 MACI
6.3.9 Laviv
6.3.10 Gendicine
6.3.11 Oncorine
6.3.12 Neovasculgen
6.3.13 Strimvelis
6.3.14 Invossa
6.3.15 Zolgenesma
6.3.16 Tecartus
6.3.17 Lisocel
6.3.18 Zyntelego
6.3.19 Others
6.4 Global Cell and Gene Therapy Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Ambulatory Surgical Centres
6.4.4 Wound Care Centres
6.4.5 Cancer Care Centres
6.4.6 Others
6.5 Global Cell and Gene Therapy Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Cell and Gene Therapy Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cell and Gene Therapy Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cell and Gene Therapy Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cell and Gene Therapy Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cell and Gene Therapy Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Amgen, Inc.
17.1.1 Financial Analysis
17.1.2 Financial Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Bluebird Bio, Inc.
17.2.1 Financial Analysis
17.2.2 Financial Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Castle Creek Pharmaceutical Holdings
17.3.1 Financial Analysis
17.3.2 Financial Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Kite Pharma, Inc.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Novartis AG
17.5.1 Financial Analysis
17.5.2 Financial Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Orchard Therapeutics plc.
17.6.1 Financial Analysis
17.6.2 Financial Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Pfizer, Inc.
17.7.1 Financial Analysis
17.7.2 Financial Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Spark Therapeutics, Inc.
17.8.1 Financial Analysis
17.8.2 Financial Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Vericel Corporation
17.9.1 Financial Analysis
17.9.2 Financial Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Human Stem Cells Institute
17.10.1 Financial Analysis
17.10.2 Financial Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Kolon Tissuegene Inc.
17.11.1 Financial Analysis
17.11.2 Financial Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Organogenesis Holdings Inc.
17.12.1 Financial Analysis
17.12.2 Financial Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Cell and Gene Therapy Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Amgen, Inc.
  • Bluebird Bio, Inc.
  • Castle Creek Pharmaceutical Holdings
  • Kite Pharma, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Pfizer, Inc.
  • Spark Therapeutics, Inc.
  • Vericel Corporation
  • Vericel Corporation
  • Human Stem Cells Institute
  • Kolon Tissuegene Inc.
  • Organogenesis Holdings Inc.

Methodology

Loading
LOADING...

Table Information